14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CLDX vs RAPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Celldex Therapeutics, Inc (CLDX) on higher Unified Composite conviction (52.4/100 HOLD vs. 55.7/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality), while CLDX wins 3–1 across the 6-pillar growth and valuation breakdown. CLDX trades at $28.71 (N/M Forward P/E, -211684.8% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CLDX currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. RAPT 52.4/100 HOLD), RAPT captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -211684.8% operating margin) and revenue trajectory (-100.0% vs. -97.0% YoY).
Technical & Structure Timing Caution: CLDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.6); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLDX vs RAPT. Trailing 12-month operating profitability (CLDX -211684.8% vs RAPT 0.0%) and valuation multiples (CLDX N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLDX vs RAPT Key Questions & Quantitative Answers
As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Celldex Therapeutics, Inc (CLDX) on higher Unified Composite conviction (52.4/100 HOLD vs. 55.7/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality), while CLDX wins 3–1 across the 6-pillar growth and valuation breakdown. CLDX trades at $28.71 (N/M Forward P/E, -211684.8% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CLDX currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. RAPT 52.4/100 HOLD), RAPT captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -211684.8% operating margin) and revenue trajectory (-100.0% vs. -97.0% YoY). Technical & Structure Timing Caution: CLDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.6); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLDX leads the Growth & Scale pillar: CLDX posts -97.0% YoY revenue growth and +0.0% YoY earnings growth on $158,000 TTM revenue (N/A gross margin, -211684.8% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLDX generates $158,000 in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, CLDX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.
CLDX and RAPT trade at balanced relative valuation multiples. CLDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLDX (-49.5% ROE) versus RAPT (-85.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CLDX carries 134.4% implied volatility (56th %ile, Balanced (25th–60th %ile)), a 0.70x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.06β · 46% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.